ArticleClinical pharmacology and therapeutics2020

PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.

Kevin Smart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.